Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | PEPD | P12955 | 2/20 | 0.36 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17001850 | 1.00 | FKBP1A (0.44) | FKBP1APOLBALDH1A1LTA4HPEPD | |
| SCHEMBL12881541 | 1.00 | FKBP1A (0.44) | FKBP1APOLBALDH1A1LTA4HPEPD | |
| SCHEMBL17001902 | 0.95 | FKBP1A (0.43) | FKBP1APOLBALDH1A1CASP3SLC6A2 | |
| SCHEMBL12881544 | 0.95 | FKBP1A (0.43) | FKBP1APOLBALDH1A1CASP3SLC6A2 | |
| SCHEMBL17001967 | 0.94 | FKBP1A (0.42) | FKBP1APOLBALDH1A1CNR1CNR2 | |
| SCHEMBL18477112 | 0.90 | FKBP1A (0.40) | FKBP1APOLBALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL18477421 | 0.90 | FKBP1A (0.40) | FKBP1APOLBALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL2913400 | 0.90 | POLB (0.46) | FKBP1APOLBPEPDXPNPEP1CNR1 | |
| SCHEMBL2913398 | 0.90 | POLB (0.46) | FKBP1APOLBPEPDXPNPEP1CNR1 | |
| SCHEMBL24434718 | 0.86 | POLB (0.44) | FKBP1APOLBALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | FKBP1A 4218/4885POLB 3277/4885ALDH1A1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.